CLAIMS

1. A method of treating an eye disorder in a patient, wherein (i) the patient is administered a therapy, and (ii) the patient's response to treatment is monitored remotely by the physician using a remote device that is able to carry out a sight test and supply the results to the physician.

2. The method of claim 1, further comprising the step of (iii) altering the patient's treatment regime such that visual function is maintained.

3. A method of determining when a patient suffering from an eye disorder requires retreatment, comprising the steps of (i) measuring the patient's visual function, (ii) administering a therapy, (iii) monitoring the patient's visual function remotely using a remote device that is able to carry out a sight test and supply the results to the physician, and (iv) retreating the patient when visual function drops below a threshold level.

4. The method of any one of claims 1-3, wherein the patient is administered a VEGF antagonist.

5. A VEGF antagonist for use in treating an eye disorder, wherein the patient's response to treatment is monitored remotely by the physician using a remote device that is able to carry out a sight test and supply the results to the physician.

6. The use according to claim 5, further comprising the step of altering the patient's treatment regime such that visual function is maintained above a threshold level.

7. The method according to any of claims 1-4 or use according to claim 5 or claim 6 wherein the eye disorder being treated is selected from: choroidal neovascularisation, age-related macular degeneration (both wet and dry forms), macular edema secondary to retinal vein occlusion (RVO) including both branch RVO (bRVO) and central RVO (cRVO), choroidal neovascularisation secondary to pathologic myopia (PM), or diabetic macular edema (DME).

8. The method or use according to any previous claim, wherein the remote device is hand held.

9. The method or use according to claim 8, wherein the hand held device is a PDA, gaming console or smart phone.

10. The method or use according to any previous claim, wherein the sight test is the dynamic shape discrimination vision test described in US2009/0273758.

11. The method or use according to any previous claim, wherein the results of the test are sent realtime to the physician.

12. The method or use according to any previous claim, wherein the patient is treated with ranibizumab, bevacizumab or VEGF Trap-Eye (aflibercept).

13. The method or use according to any of claims 7-12, wherein the sight test is the amsler grid test, snellen acuity chart, "tumbling E" chart, "Landolt C" chart, moving line test, crosshair alignment pattern test or the SDH test.

14. The method or use according to claim 13, wherein the sight test is the SDH test, "tumbling E" chart or "Landolt C" chart.

15. The method or use according to claim 14, wherein treatment is administered until no further improvement in visual function is seen following two or more (i.e. 2, 3, 4, 5 or more) consecutive treatments.

16. The method or use according to claim 14, wherein treatment is administered until the patient achieves a best corrected visual acuity (BCVA) score of 80 or more (i.e. 81, 82, 83, 84, 85, 86, 87, 88, 89, 90 or more) following two or more (i.e. 2, 3, 4, 5 or more) consecutive treatments.

17. The method or use according to claim 14, wherein treatment is administered until no further improvement is seen following two or more (i.e. 2, 3, 4, 5 or more) consecutive treatments, as determined by the SDH test score.

18. The method or use according to any of claims 14-17, wherein retreatment is given when the patient's score (i.e. number of correct answers) in two or more (i.e. 2, 3, 4, 5, 7, 10 or more) consecutive tests decreases by x%, compared to the average score over the preceding y days, wherein x is 1%, 2%, 3%, 5%, 10% or more, and y is 3, 5, 7, 10, 12, 14, 15, 21 days or more.

19. The method or use according to any of claims 14-17, wherein retreatment is given when the patient's visual function declines by 1%, 2%, 3%, 5%, 10% or more from a baseline level.

20. The method or use according to claim 19, wherein said baseline level is the stable level achieved causing the cessation of treatment.

21. The method or use according to any previous claim, wherein the VEGF antagonist is (a) ranibizumab administered at a dose of 0.5mg, or (b) aflibercept administered at a dose of 2mg.

22. The method or use according to any previous claim, wherein the patient completes the dynamic shape discrimination vision test daily and is examined by the physician monthly.

23. The method or use according to any previous claim, wherein patient self-administers the therapy and the device instructs when the therapy should be administered according to a pre-determined algorithm.

24. The method or use according to any previous claim, wherein following a significant decrease in visual function as determined by the device, the physician is automatically alerted and an emergency appointment for the patient to see the physician is made.

25. The method or use according to any previous claim, wherein the patient consecutively completes two or more types of vision test disclosed in claim 13.

26. A kit comprising a remote device, vision testing software and instructions for use in the method or use of any one of claims 1-24.

27. The kit of claim 26, further comprising a therapeutic agent.

28. The kit of claim 27, wherein said therapeutic agent is a VEGF antagonist.

29. The kit of any of claims 26-28, wherein said kit further comprises a delivery device and instructions for use.

CLAIMS

1. A VEGF antagonist for use in the treatment of eye disorder, wherein the patient's response to treatment is monitored remotely by the physician using a remote device that is able to carry out a sight test and supply the results to the physician.

2. The use according to claim 1, further comprising the step of measuring the patient's visual function.

3. The use according to claim 1 or 2, further comprising the step of altering the patient's treatment regime such that visual function is maintained above a threshold level.

4. The use according to any previous claim wherein the eye disorder being treated is selected from: choroidal neovascularisation, age-related macular degeneration (both wet and dry forms), macular edema secondary to retinal vein occlusion (RVO) including both branch RVO (bRVO) and central RVO (cRVO), choroidal neovascularisation secondary to pathologic myopia (PM), or diabetic macular edema (DME).

5. The use according to any previous claim, wherein the remote device is hand held.

6. The use according to claim 5, wherein the hand held device is a PDA, gaming console or smart phone.

7. The use according to any previous claim, wherein the sight test is the dynamic shape discrimination vision test described in US2009/0273758.

8. The use according to any previous claim, wherein the results of the test are sent realtime to the physician.

9. The use according to any previous claim, wherein the patient is to be treated with ranibizumab, bevacizumab or VEGF Trap-Eye (aflibercept).

10. The use according to any of claims 4-9, wherein the sight test is the amsler grid test, snellen acuity chart, "tumbling E" chart, "Landolt C" chart, moving line test, crosshair alignment pattern test or the SDH test.

11. The use according to claim 10, wherein the sight test is the SDH test, "tumbling E" chart or "Landolt C" chart.

12. The use according to claim 11, wherein treatment is to be administered until no further improvement in visual function is seen following two or more consecutive treatments.

13. The use according to claim 11, wherein treatment is to be administered until the patient achieves a best corrected visual acuity (BCVA) score of 80 or more following two or more consecutive treatments.

14. The use according to claim 11, wherein treatment is administered until no further improvement is seen following two or more consecutive treatments, as determined by the SDH test score.

15. The use according to any of claims 11-14, wherein retreatment is given when the patient's score (i.e. number of correct answers) in two or more consecutive tests decreases by x%, compared to the average score over the preceding y days, wherein x is 1%, 2%, 3%, 5%, 10% or more, and y is 3, 5, 7, 10, 12, 14, 15, 21 days or more.

16. The use according to any of claims 11-14, wherein retreatment is to be given when the patient's visual function declines by 1%, 2%, 3%, 5%, 10% or more from a baseline level.

17. The use according to claim 16, wherein said baseline level is the stable level achieved causing the cessation of treatment.

18. The use according to any previous claim, wherein the VEGF antagonist is (a) ranibizumab to be administered at a dose of 0.5mg, or (b) aflibercept to be administered at a dose of 2mg.

19. The use according to any previous claim, wherein the patient is to complete the dynamic shape discrimination vision test daily and is to be examined by the physician monthly.

20. The use according to any previous claim, wherein patient is to self-administer the therapy and the device instructs when the therapy should be administered according to a pre-determined algorithm.

21. The use according to any previous claim, wherein following a significant decrease in visual function as determined by the device, the physician is automatically alerted and an emergency appointment for the patient to see the physician is made.

22. The use according to any previous claim, wherein the patient consecutively completes two or more types of vision test disclosed in claim 10.

23. A kit comprising a remote device, vision testing software and instructions for the use of any one of claims 1-21.

24. The kit of claim 23, further comprising a therapeutic agent.

25. The kit of claim 24, wherein said therapeutic agent is a VEGF antagonist.

26. The kit of any of claims 23-25, wherein said kit further comprises a delivery device and instructions for use.